Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.57 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2498876 | 0.85 | MAOB (0.64) | MAOBNR4A1NR4A2NR4A3ALDH1A1 | |
| SCHEMBL8913237 | 0.81 | NR4A2 (0.66) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL102983 | 0.80 | RAB9A (0.83) | MAOBNR4A1NR4A2NR4A3PARP10 | |
| SCHEMBL2303273 | 0.79 | PDPK1 (0.51) | SMN1; SMN2MAPTHDAC3HDAC1HDAC2 | |
| SCHEMBL6515252 | 0.79 | PDPK1 (0.51) | SMN1; SMN2MAPTHDAC3HDAC1HDAC2 | |
| SCHEMBL2303277 | 0.79 | PDPK1 (0.51) | SMN1; SMN2MAPTHDAC3HDAC1HDAC2 | |
| SCHEMBL7486774 | 0.79 | ESR1 (0.44) | NR4A1NR4A2NR4A3ALDH1A1SMN1; SMN2 | |
| SCHEMBL434843 | 0.79 | CA1 (0.53) | PARP10ALDH1A1HTTSMN1; SMN2HDAC3 | |
| SCHEMBL8474022 | 0.79 | CA1 (0.53) | PARP10ALDH1A1HTTSMN1; SMN2HDAC3 | |
| SCHEMBL8474020 | 0.79 | CA1 (0.53) | PARP10ALDH1A1HTTSMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | MAOB 300/4885NR4A1 826/4885NR4A2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.